← Home / BRIACELL THERAPEUTICS CORP. (BCTX)
Stock Analysis
BRIACELL THERAPEUTICS CORP. (BCTX)
BCTX
BCTX · Market data
3.44 -5.23%
Track BCTX in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when BCTX price is:
52W Range Position
6%
LOWMIDHIGH
Trend
Mixed
Momentum
Neutral
Updated: 2026-08-02 16:44 UTC
WOI Investment Thesis
Mixed
Confirmation improves above 3.56. Holding above 3.37 keeps the current thesis intact.
⚖️
✓
Fundamentals
Insufficient / Insufficient
✓
Price Structure
Mixed
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Elevated
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
3.37
↗
Break Above
Confirmation improves above resistance.
3.56
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below 3.37
Recent Company Events
SEC VERIFIED
Latest material filings
JUN
26
●
Material Agreement
MEDIUM
MANAGEMENT’S
DISCUSSION AND ANALYSIS For the three and nine months ended April 30, 2026 (Expressed in U.S.
8-K Filing • SEC EDGAR
JUN
3
↗
Equity Offering / Capital Raise
HIGH
BCTX equity financing update
On May 31, 2026, BriaCell Therapeutics Corp.
8-K Filing • SEC EDGAR
What's Driving BCTX?
📈 Technical recovery is improving
Momentum is Neutral. Watch 3.56 for confirmation and 3.37 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
Below 3.37
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
47.4
Price Chart
BCTX — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$24.9M
Company size
EV
$18.1M
Debt-adjusted value
P/E
-0.8
Not meaningful
P/B
1.1
Low book multiple
EV/EBIT
-0.6
Not meaningful
P/FCF
-0.8
Not meaningful
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial context is mixed
Financial conditions require selective monitoring.
↗
Revenue Growth
Insufficient
●
Profitability
Insufficient
≈
Cash Flow
Recovering
⚖
Balance Sheet
Strong
📈 Net Income
-7.16M
≈ Insufficient
🧮 EPS (Basic)
-0.99
≈ Insufficient
BRIACELL THERAPEUTICS CORP.
Related Opportunities